Phase 2 Trial of Tau Antibody RO7105705 Recruiting Patients with Moderate Alzheimer’s

Phase 2 Trial of Tau Antibody RO7105705 Recruiting Patients with Moderate Alzheimer’s
A Phase 2 trial is enrolling patients with moderate Alzheimer’s to test an investigational antibody known as RO7105705 that targets the Tau protein. The Genentech-sponsored multicenter, randomized study (NCT03828747) intends to assess the efficacy, safety, and pharmacological profile of RO7105705. The company plans to recruit 260 patients in the U.S. More information on study locations and contacts can be found here. After a screening period, patients will receive RO7105705 or placebo by intravenous infusion every two weeks for the first three doses and every four weeks thereafter in a double-blind treatment period. Participants can then undergo an optional open-label extension period which will consist of RO7105705 infusions every four weeks. The last stage will be a safety follow-up period. The trial's primary goal is measuring the change in cognitive function and functional abilities from baseline to week 49. RO7105705, or MTAU9937A, is being developed by Genentech — owned by Roche — and AC Immune. The treatment candidate is a humanized monoclonal antibody, designed to stop the cell-to-cell spread of toxic forms of the Tau protein in the brain. This spread is associated with the onset and progression of cognitive decline in Alzheimer’s disease. “Slowing the propagation of Tau pat
Subscribe or to access all post and page content.

One comment


    An problem with Alzheimer’s disease is that all the successful studies in transgenic mouse models have delivered only clinical failures. Apparently, if a product does not work in the mouse model would not work at all in humans, but, if it is effective in that animal model, there are no assurances that it will work in humans.
    A potential problem with the monoclonal antibody studies, is that based on the artificial animal model the antibody is always focused on a single lesion; yet, in humans there are indications that amyloid-beta and tau, have a gamma of structural alterations. Hence, blocking one would not affect the others; therefore, it is possible to postulate that a more effective approach would be to use batteries of antibodies against different alterations, i.e. mimic the natural polyclonal antibodies. Another advantage of using various antibodies is the cooperative effects among different antibodies, which would improve their effects on the apparently heterogeneous population of aberrant protein species. In fact, trying to apply directly concepts derived from hormones and their receptors to Alzheimer’s disease, is apparently a good recipe for failure

Leave a Comment

Your email address will not be published. Required fields are marked *